龙虎榜机构热股 | 上榜热股 | 实时涨跌幅 | 买/卖家数 | | | --- | --- | --- | --- | | 利欧股份 002131.SZ | +1.04% | 3/0 | +2 | | 迈威生物 688062.SS | +2.73% | 1 / 0 | +1 | | 3日 | | | | 今天机构龙虎榜上榜36只个股，净买入17只，净卖出19只。当日机构买入最多的个股前三位是：利欧股份（2.22亿）、迈威生物（3日1.09亿）、英维克 （9329万）。 利欧股份 今日龙虎榜显示，3家机构净买入2.22亿。 9月2日，利欧股份收盘价5.85元，为低价股。另外公司8月8日公告称，董事会审议通过了《关于使用自有资金进行证券投资的议案》，同意公司及下属子公 司使用最高额度不超过 30 亿元人民币（或投资时点等值外币）的自有资金进行证券投资。 龙虎榜知名游资 秦川机床 个股龙虎榜 一、机器人 据证券时报报道，据市场上流传的信息，某机器人龙头上市公司今天应该与特斯拉举行了会议，特斯拉对明年的产能给出了非常乐观的指引。该传闻指，特 斯拉要求该公司明年一季度做好产能爬坡的准备，明年三季度单周产能可能达1万台 ...

证券代码：688062 证券简称：迈威生物 公告编号：2025-050 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 迈威（上海）生物科技股份有限公司（以下简称"公司"）股票于 2025 年 8 月 29 日、9 月 1 日和 9 月 2 日连续三个交易日内日收盘价格涨幅偏离值累 计超过 30%。根据《上海证券交易所交易规则》《上海证券交易所科创板股票异 常交易实时监控细则》的有关规定，属于股票交易异常波动情形。 经公司自查并书面发函向控股股东、实际控制人及其一致行动人书面核 实，截至本公告披露日，确认不存在应披露而未披露的重大事项或重要信息。 公司股价短期波动幅度较大，敬请广大投资者注意市场交易风险，审慎 决策，理性投资。 一、股票交易异常波动的具体情况 公司股票于 2025 年 8 月 29 日、9 月 1 日和 9 月 2 日连续三个交易日内日收 盘价格涨幅偏离值累计超过 30%，根据《上海证券交易所交易规则》《上海证券 交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动 情形。 ...

中国经济网北京9月2日讯 迈威生物（688062.SH）近日披露2025年半年度报告，上半年公司实现营业收入1.01亿元，同比 下降12.43%；归属于上市公司股东的净利润为-5.51亿元，上年同期为-4.44亿元；归属于上市公司股东的扣非净利润为-5.74亿 元，上年同期为-4.61亿元；经营活动产生的现金流量净额为-3392.45万元，上年同期为-4.62亿元。 另外，迈威生物2025年8月31日晚间披露关于重新向香港联交所递交H股发行并上市的申请并刊发申请资料的公告。 迈威生物于2022年1月18日在上交所科创板上市，发行股份数量为9990.00万股，发行价格为34.80元/股，保荐机构（主承销 商）为海通证券（现名国泰海通），保荐代表人为王永杰、陈新军。 | 中 | | --- | | 申 | | ﺎ 1 117 种: 人民 JL E | | 主要会计数据 | 本报告期 (1-6月) | 上年同期 | 本报告期比上年 同期增减(%) | | --- | --- | --- | --- | | 营业收入 | 101.165.449.14 | 115,528,061.72 | -12.43 | | 利润总 ...

持续亏损的迈威生物(688062.SH)，再度递表港交所。 8月31日晚间，迈威生物发布公告称，公司已于8月29日向香港联合交易所有限公司重新递交了发行H股 股票并在香港联交所主板挂牌上市的申请。 截至2025年上半年末，迈威生物资产负债率达77.54%，创下新高。同时，公司现金流日趋紧张。 长江商报记者发现，自2017年有可查数据以来，迈威生物一直处于亏损之中。 综合来看，8年半来，迈威生物营业收入累计约5.5亿元，净利润亏损约62.7亿元。 不过，迈威生物在研发上的投入也不少，8年半来研发费用累计达46.13亿元。 对于赴港IPO的目的，迈威生物此前表示，为满足公司经营发展的资金需求，实现公司可持续发展，提 升公司国际化水平。 负债率创新高，现金流紧张 迈威生物是一家全产业链布局的创新型生物制药公司，主营业务为研发、生产以及销售创新型药物和生 物类似药，主要产品为抗体、ADC药物和重组蛋白、小分子化学药等药物。 8月31日晚间，迈威生物发布公告称，公司已于8月29日向香港联合交易所有限公司重新递交了发行H股 股票并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行的申请资料。 迈威生物 ...

证券研究报告·公司深度研究·药品及生物科技(HS) 迈威生物-U（688062） IL-11 单抗全球领先，战略布局抗衰老及病理 性瘢痕等 买入（维持） ◼ 多款重磅管线厚积薄发：1）9MW1911：国内进度最快、全球第二的 ST2 单抗 COPD 患者的 Ib/IIa 期 80 例患者已全部入组，预计 2025 年 H2 完成随访，力争年底前后读出有效性数据；2）9MW2821：全球进度 领先、具 BIC 潜力的 Nectin-4 ADC，临床数据优异 ——1.25mg/kg 推 荐剂量下，对尿路上皮癌、宫颈癌、食管癌、三阴性乳腺癌的疾病控制 率分别达 91.9%、81.1%、67.4%、80%，多个肿瘤适应症 III 期临床推 进中，最早 2026 年有望提交 BLA；3）7MW4911 与 7MW3711：基于 IDDC 平台的 ADC 药物，分别靶向 CDH17 与 B7-H3，采用毒素升级 的新结构喜树碱衍生物，具备抗毒素耐药疗效，更好满足临床需求；4） TCE 平台管线：自主搭建 TCE 平台，2MW7061（CD3; LILRB4）为公 司首款预计进入临床的 TCE 药物，适应症为 AML。 ◼ ...

Group 1 - The closing price of Maiwei Biotech (688062) on September 1 was 57.60 yuan, reaching the daily limit with a trading volume of 1.496 billion yuan and a turnover rate of 12.96% [2] - The stock was listed on the daily trading list due to a price increase of 15% at the close [2] - The top five trading departments accounted for a total transaction of 555 million yuan, with a net buying amount of 87.24 million yuan [2] Group 2 - The main buying department included the Shanghai-Hong Kong Stock Connect, which had a buying amount of 178.71 million yuan, while the main selling department was also the Shanghai-Hong Kong Stock Connect with a selling amount of 91.63 million yuan [3] - Overall, the stock experienced a net outflow of 6.60 million yuan in main funds throughout the day [3] - Specific buying amounts from other departments included 48.45 million yuan from Guotai Junan Securities and 33.64 million yuan from an institutional special seat [3]

8月31日晚间，迈威生物发布公告，重新向香港联交所递交H股发行并上市的申请，并于同日在香港联 交所网站刊登了本次发行的申请资料。上述公告披露后，9月1日，迈威生物股价大幅上涨，截至午间收 盘涨停，股价为57.6元，涨幅20%。自上市以来截至9月1日午间收盘，其股价累计涨幅为65.52%，总市 值230.17亿元。 高研发投入下，业绩持续亏损 迈威生物成立于2017年，是一家全产业链布局的创新型生物制药公司，专注于肿瘤和年龄相关疾病，如 免疫、眼科、骨科等领域。 2022年1月18日，迈威生物成功登陆科创板，资本市场对其寄予厚望。同年3月，迈威生物首款产品阿达 木单抗生物类似药君迈康获批上市，截至目前已有4款商业化产品，分别为今年5月底刚获批上市的1类 创新药注射用阿格司亭α（商品名：迈粒生），以及三款生物类似药：阿达木单抗生物类似药君迈康、 地舒单抗（普罗力）的生物类似药迈利舒（60mg）、地舒单抗（安加维）的生物类似药迈卫健 （120mg），研发管线中拥有10余款处于临床前、临床或上市阶段的品种。 同时，随着4款产品相继获批上市，迈威生物的营销体系建设也需要资金投入，销售费用的投入也不 小。2022年、20 ...

9月1日，A股市场继续上攻。尽管金融股表现不佳并拖累了大盘，但沪指仍微幅上涨。 科技成长股依旧火热，创业板指逼近3000点。市场交易活跃度较高，日成交额微降至2.78万亿元，但市场分化明 显，有3208只个股收涨。截至8月29日，沪深京两融余额增至2.26万亿元。 多位受访人士表示，当下需要注意一些风险。例如，TMT（科技、媒体和通信）与医药板块短期交易拥挤，融资 盘占比抬升。一旦监管层对量化交易或两融窗口指导，高弹性板块可能出现剧烈回撤。预计本周指数仍将呈"沪稳深 强"的震荡抬升格局，即沪指在3850至3930点区间反复拉扯，创指则有望挑战2600点上方的筹码密集区。 3208只个股收涨 | 名称 | . | ****** | 最新 | 总市值 | 成交额 | 周涨幅% | 月涨幅% | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 有色金属(申) | | | 3.46 6635.29 | 41773 Z | 1763亿 | BA6 | 346 | 53.67 | | 院程科技 | 1 | 13.43 | 22.38 ...

Company Overview - Maiwei Biotech (688062.SH) experienced a significant stock price increase, closing at a historical high of 57.60 yuan per share, with a market capitalization of 23.017 billion yuan [1] - The company has submitted a new application for an IPO in Hong Kong and received formal acceptance for its Phase II clinical trial of 9MW3811 injection for pathological scars, with plans to initiate patient enrollment by the end of this year [1][2] Product Development - 9MW3811 is a humanized monoclonal antibody targeting IL-11, which is closely related to aging-related diseases. The drug has shown potential in treating fibrosis-related diseases by inhibiting the abnormal activation of the IL-11/IL-11Rα signaling pathway [2][3] - The drug has received approval for clinical studies in China, the United States, and Australia for advanced malignancies and idiopathic pulmonary fibrosis, with Phase I trials completed in Australia and China [2] Market Potential - The global incidence of pathological scars (HSK) is approximately 25 million, with around 7.4 million cases in China, projected to exceed 10 million by 2030 [3] - The aging intervention market has seen a surge in investment, with total financing in the sector reaching $8.49 billion in 2024, a 122% increase from $3.82 billion in 2023 [1][4] Strategic Partnerships - In June, Maiwei Biotech entered into an exclusive licensing agreement with Calico, a Google-affiliated anti-aging giant, for the development and commercialization of IL-11 targeted therapies outside of China, potentially yielding up to $571 million in milestone payments and royalties [4][7] Competitive Landscape - Maiwei Biotech is the first company in China to develop an IL-11 antibody drug, with 9MW3811 being the first to explore the pathological scar indication in clinical trials [3] - The competitive landscape includes similar drugs like BI 765423 from Boehringer Ingelheim, which has also entered Phase I clinical trials [2]

Group 1 - Weisheng Information won four projects in August with a total amount of 85.5377 million yuan, accounting for 3.12% of the company's total revenue for 2024 [1] - Longqi Technology's shareholder plans to reduce its stake by up to 4.09%, equating to a maximum of 19.1916 million shares [1] - Guojin Modern's subsidiary received a drug registration certificate for injectable Nicardipine, used for treating unstable angina [3][4] Group 2 - SAIC Motor reported a total vehicle sales of 363,400 units in August, a year-on-year increase of 41.04%, with new energy vehicle sales reaching 129,800 units, up 49.89% [5] - Kuka Home plans to invest 1.124 billion yuan to build a self-owned base in Indonesia, aiming to enhance its international strategy [6] - Samsung Medical's subsidiary signed a contract for an intelligent meter project in Egypt worth 58.8 million USD, approximately 419 million yuan [8] Group 3 - North Vehicle Blue Valley's subsidiary reported a total production of 10,587 units in August, a year-on-year decrease of 15.13%, while sales increased by 3.47% [12] - Xianghe Industrial signed contracts worth 400 million yuan for railway fastener system components [13] - Hengrui Medicine's HRS9531 injection has received acceptance for its marketing authorization application [14] Group 4 - Hualu Hengsheng resumed normal production after completing maintenance on production facilities [16] - Shanghai Pharmaceuticals' hydrochloride verapamil injection passed the consistency evaluation for generic drugs [18] - Shanghai Construction received approval for debt financing tools with a registration period of two years [20] Group 5 - Kangli Elevator terminated the sale of its wholly-owned subsidiary due to the buyer's failure to obtain necessary approvals [21] - Times Wan Heng appointed Li Zhizhong as the new deputy general manager [22] - Hanma Technology reported a total truck sales of 1,051 units in August, a year-on-year increase of 58.05% [24] Group 6 - Wenzhou Hongfeng's subsidiary received a utility model patent certificate for a servo adjustment device [26] - Yibin Technology received a project designation from a domestic new energy vehicle company, with an estimated total sales of 243 million yuan over five years [28] - Star Ring Technology's H-share issuance application was accepted by the China Securities Regulatory Commission [30] Group 7 - Microchip Bio's vice president resigned for personal reasons [31] - Zhongxin Co. announced the resignation of a non-independent director due to personal reasons [32] - Changcheng Military Industry's vice chairman resigned due to retirement [35] Group 8 - Jiukang Bio received four invention patent certificates related to detection reagents [36] - Meino Bio's subsidiary changed its registered address [37] - Kuangda Technology announced a potential change in control due to a share transfer [38] Group 9 - China Rare Earth confirmed no undisclosed significant matters amid stock price fluctuations [72]